Mountain Valley MD AI Stock Analysis
Want to see TSE:MLCO full AI Analyst Report?
Mountain Valley MD (MLCO) AI Stock Analysis
Mountain Valley MD
(CNQX:MLCO)
The overall score of 42 reflects a high-risk, pre-revenue biotechnology company in financial distress. The most significant factor is the precarious financial performance, characterized by a rapid cash burn rate and minimal revenue that is vastly outpaced by operating losses. This is compounded by a persistently bearish technical trend, with the stock price trading below all major moving averages, indicating strong negative market momentum. The negative P/E ratio further confirms the lack of current earnings power. The company's survival is contingent on securing additional financing or achieving a dramatic, and currently unproven, revenue ramp.
Mountain Valley MD (MLCO) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 20.57M
- Dividend Yield
- ―
- Average Volume (3M)
- 117.65K
- Price to Earnings (P/E)
- -4.6
- Beta (1Y)
- -0.69
- Revenue Growth
- 48.94%
- EPS Growth
- 53.81%
- Country
- Canada
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Mountain Valley MD Business Overview & Revenue Model
Company Description
The More Life Co. Corp. is a biotechnology company, which engages in the provision of solutions to optimize human, animal, and plant health. Its patented technologies includes Quicksomeâ„¢ and Quicksolâ„¢. The Quicksomeâ„¢ patented technology utilizes prop...
Mountain Valley MD Financial Statement Overview
Summary
Financial health is precarious. The company has minimal revenue ($70k TTM) and deep net losses (-$3.7M TTM). The balance sheet is debt-free but assets have shrunk to $1.84M from $8.97M, and the cash burn rate is severe with -$2.2M in operating cash flow. The recent capital raise provides a temporary lifeline but does not resolve the fundamental lack of profitability.
Income Statement
18Very NegativeBalance Sheet
35NegativeCash Flow
22Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.00K | 65.00K | 49.00K | 60.00K | 0 | 110.00K |
| Gross Profit | 37.00K | -2,000 | 49.00K | -346.00K | -446.00K | 70.00K |
| EBITDA | -2.26M | -2.27M | -3.16M | -2.78M | -6.89M | -9.29M |
| Net Income | -2.79M | -2.79M | -7.47M | -7.67M | -7.44M | -9.71M |
Balance Sheet | ||||||
| Total Assets | 524.00K | 524.00K | 2.74M | 8.97M | 16.77M | 25.27M |
| Cash, Cash Equivalents and Short-Term Investments | 334.00K | 334.00K | 1.72M | 5.92M | 9.71M | 14.22M |
| Total Debt | 403.00K | 403.00K | 0 | 0 | 6,000 | 44.00K |
| Total Liabilities | 665.00K | 665.00K | 209.00K | 258.00K | 591.00K | 422.00K |
| Stockholders Equity | -141.00K | -141.00K | 2.53M | 8.71M | 16.18M | 24.85M |
Cash Flow | ||||||
| Free Cash Flow | -2.12M | -2.12M | -3.91M | -3.80M | -4.85M | -5.68M |
| Operating Cash Flow | -2.11M | -2.11M | -3.90M | -3.30M | -4.79M | -5.59M |
| Investing Cash Flow | 200.00K | 200.00K | -290.00K | -503.00K | 1.89M | -98.00K |
| Financing Cash Flow | 519.00K | 519.00K | 0 | -6,000 | -1.60M | 395.00K |
Mountain Valley MD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MLCO, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 40.81 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MLCO.
Mountain Valley MD Peers Comparison
Overall Rating
TSE:LOBE43Neutral
TSE:MLCO42Neutral
TSE:PCLO39Underperform
TSE:RVV39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | CAD 15.41M | -2.43 | -338.76% | ― | ― | 31.00% | |
| 42Neutral | CAD 20.57M | -4.64 | -443.11% | ― | 48.94% | 53.81% | |
| 39Underperform | CAD 8.41M | -2.41 | 28.59% | ― | 0.90% | 57.73% | |
| 39Underperform | CAD 6.67M | -12.50 | 26.78% | ― | ― | 90.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:MLCO | Mountain Valley Md Holdings Inc | 0.04 | 0.03 | 200.00% | |
| TSE:RVV | Revive Therapeutics | 0.01 | 0.00 | 50.00% | |
| TSE:PCLO | Pharmacielo | 0.04 | 0.00 | 0.00% | |
| TSE:LOBE | Lobe Sciences Ltd | 0.05 | 0.01 | 11.11% |
Mountain Valley MD Corporate Events
More Life Company’s Quicksome Study Shows Rapid Sublingual Testosterone Delivery
PositiveThe More Life Company reported results from an exploratory human pharmacokinetic study of its Quicksome sublingual delivery technology using USP-grade testosterone. In an eight-participant trial, 5 mg and 15 mg Quicksome tablets produced substantial...
The More Life Company Moves to U.S. Commercialization for Quicksome Compounded Drugs
PositiveThe More Life Company Corp. has signed a strategic letter of intent with an established U.S. 503A compounding pharmacy to develop, compound and commercialize Quicksomeâ„¢-enabled prescription compounded pharmaceuticals in the United States. The contemp...
The More Life Company Updates U.S. and Canadian Trading Symbols After Rebrand
PositiveThe More Life Company Corp., formerly Mountain Valley MD Holdings Inc., operates in the life sciences sector with a focus on technologies that enhance crop productivity and resilience and improve the formulation, stability and delivery of active ingr...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026
